drugset / Trial / NCT00606541

An Open Label, Double-blind Discontinuation Study of Quetiapine Extended Release(XR)

NCT00606541

Phase 0 Terminated 55 enrolled Duke University
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Purpose of Study: To examine 1) the short and long-term effectiveness and tolerability of quetiapine (extended release) XR for the treatment of social anxiety disorder (SAD); and 2) continuation effects of quetiapine XR in preventing SAD relapse.

Timeline

Start
2008-01
Primary completion
2011-12
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule 50 mg
Subject Quetiapine Small molecule 400 mg

Indications